Every Form 4 that Parabilis Medicines, Inc. (PBLS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PBLS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PBLS filings page.
Parabilis Medicines, Inc. (PBLS) reported that director Craig Tendler received a grant of 20,294 stock options on August 22, 2026. The options carry an exercise price of $39.36 per share and expire on August 21, 2036. According to the grant terms, the options will vest in 36 equal monthly installments starting August 22, 2026, conditioned on Dr. Tendler’s continued service, resulting in post-transaction direct beneficial ownership of 20,294 derivative securities.
RA Capital-affiliated funds reported open-market purchases of 244,593 shares of Parabilis Medicines voting common stock from July 20–22, 2026, at weighted average prices around $27–30 per share. The shares are held indirectly by RA Capital Healthcare Fund LP, with the adviser and principals disclaiming beneficial ownership beyond their pecuniary interests.
Parabilis Medicines’ major Soleus-affiliated holders increased their indirect stake through both conversion and open-market buying. On June 11, 2026, Soleus investment funds converted 527,070 shares of Series F Preferred Stock into common stock at $9.48 per share in an automatic conversion tied to the company’s initial public offering.
The same day, Soleus-related entities purchased an additional 500,000 common shares in open-market transactions at $20.00 per share, bringing their reported indirect common stock holdings to 1,027,000 shares for Section 16 reporting purposes.
Parabilis Medicines director Alan Sebulsky reported indirect open-market purchases of Parabilis Medicines, Inc. common stock through Apothecary Capital LLC. Across three transactions on June 12 and June 15, Apothecary Capital bought a total of 17,500 shares at weighted average prices reported as $27.6696, $25.9978 and $27.0963 per share. Following the most recent transaction, Apothecary Capital holds 30,000 shares. Footnotes state Sebulsky is the managing member of Apothecary Capital and may share voting and investment power but disclaims beneficial ownership beyond any pecuniary interest.
Parabilis Medicines, Inc. disclosed that investment vehicles managed by RA Capital made substantial purchases and conversions into its Voting Common Stock. On June 11, 2026, RA Capital–related funds completed open‑market purchases totaling 21,188,750 shares of Voting Common Stock at $20.00 per share, held indirectly through the funds. On the same date, Series E and Series F Preferred Stock automatically converted into additional Voting Common Stock immediately prior to the closing of the IPO, with Series E converting at a 1 to 0.6524 ratio and Series F at a 1 to 0.6498 ratio, without payment of consideration. The RA Capital adviser and related entities disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
Parabilis Medicines director Edward M. Fitzgerald reported a series of non-cash conversions of preferred stock into common shares. On June 11, 2026, he converted Series B, C and F Preferred Stock into Common Stock, acquiring 5,539, 3,878 and 5,271 common shares, respectively, at $0.00 per share.
These preferred shares automatically converted into common immediately prior to the closing of the company’s initial public offering on June 9, 2026, as described in the footnotes. No shares were sold; all Form 4 transactions are coded as conversions of derivative securities. Following these transactions, Fitzgerald directly holds 14,688 shares of Common Stock.
Parabilis Medicines, Inc. director-associated entity Apothecary Capital LLC made an open-market purchase of 12,500 shares of common stock at $20.00 per share on June 11, 2026. The shares are held indirectly, with Alan Sebulsky disclaiming beneficial ownership except for any pecuniary interest.
Parabilis Medicines director Alexis Borisy converted preferred stock into common shares tied to the company’s IPO. On June 11, 2026, 162,221 shares of Series F Preferred Stock were converted into 105,414 shares of Common Stock, leaving him with 105,414 common shares directly owned. According to the terms, each preferred share converted at a 1 to 0.6498 rate and automatically converted into common shares immediately before the closing of the initial public offering on June 9, 2026. This was a non-cash derivative conversion, not an open‑market purchase or sale.
Parabilis Medicines, Inc. reported that investment funds managed by Deerfield converted multiple series of preferred stock into voting common stock in connection with the company’s initial public offering. The Form 4 shows Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund III, L.P. acquiring an aggregate of 2,042,004 shares of voting common stock through automatic conversions coded as “C” transactions, all at a stated price of $0.00 per share. After these conversions, the preferred stock positions reported for Series A, B, C and D show zero remaining shares, indicating full conversion into common. The filing states that the Deerfield-affiliated reporting persons disclaim beneficial ownership beyond any indirect pecuniary interest.
Parabilis Medicines, Inc. reported that RA Capital–affiliated reporting persons filed a Form 4 for a compensation-related stock option grant linked to its common stock. The derivative award covers 20,215 shares of common stock at an exercise price of $20.00 per share and was granted at no cost.
The option vests in full on the earlier of June 9, 2027 or the date of Parabilis’ next annual stockholder meeting, subject to Dr. Simson’s continued service on that vesting date, and expires on June 8, 2036. Footnotes explain that under Dr. Simson’s arrangement with RA Capital’s investment adviser, the option is held for the benefit of RA Capital Healthcare Fund LP and RA Capital Nexus Fund III, L.P., and net proceeds from any exercise will offset advisory fees, with all reporting persons disclaiming beneficial ownership except for any pecuniary interest.
Parabilis Medicines, Inc. director Alexis Borisy received a grant of stock options covering 20,215 shares of common stock. The options have an exercise price of $20.00 per share and expire on June 8, 2036.
These options vest and become exercisable in full on the earlier of June 9, 2027 or the date of the company’s next annual meeting of stockholders, subject to Borisy’s continued service. Following this grant, Borisy holds 20,215 stock options directly, according to the filing.
Parabilis Medicines director Barbara Weber received a grant of stock options for 20,215 shares of common stock. The options have an exercise price of $20.00 per share and expire on June 8, 2036. They vest in full on the earlier of June 9, 2027 or the company’s next annual stockholder meeting, subject to her continued service.
Parabilis Medicines director Yeshwant Krishna received a grant of stock options as compensation. The award covers 20,215 options to buy common stock at an exercise price of $20.00 per share, expiring on June 8, 2036. These options vest and become exercisable in full on the earlier of June 9, 2027 or the company’s next annual meeting of stockholders, contingent on his continued service. After this grant, he holds 20,215 derivative securities directly.
Parabilis Medicines, Inc. director Edward M. Fitzgerald received a grant of stock options covering 20,215 shares of common stock. The options have an exercise price of $20.0000 per share and expire on June 8, 2036. The underlying 20,215 shares will vest and become exercisable in full on the earlier of June 9, 2027 or the date of the issuer's next annual meeting of stockholders, subject to his continued service on that vesting date.
Parabilis Medicines, Inc. director Jake Simson received a stock option grant covering 20,215 shares of common stock. The option has a conversion price of $20.00 per share and expires on June 8, 2036.
The option vests and becomes exercisable in full on the earlier of June 9, 2027 or the date of the company’s next annual stockholder meeting, as long as Simson continues to serve on the board through that vesting date. After this award, he holds 20,215 option-derived shares directly.
Parabilis Medicines, Inc. director Richard Klausner reported a compensation-related stock option grant. He received options covering 20,215 shares of common stock at an exercise price of $20.00 per share, with no cash paid at grant.
The options vest and become exercisable in full on the earlier of June 9, 2027 or the date of the company’s next annual meeting of stockholders, as long as he continues serving through that date. Following this award, he holds stock options for 20,215 underlying shares in this filing, reflecting a routine equity incentive grant rather than an open-market purchase or sale.
Parabilis Medicines director Alan Sebulsky received a grant of stock options, not common shares. He was awarded 39,792 options to buy Parabilis Medicines common stock at an exercise price of $20.00 per share. These options vest in 36 equal monthly installments starting June 9, 2026 and expire on June 8, 2036. After this grant, he holds 39,792 stock options directly.